PHAGOBURN is the project name of the first European clinical study on phage therapy to treat Escherichia coli and Pseudomonas aeruginosa skin infections in burn patients.

The project is funded by the 7th Framework Programme for Research and Development (Health Programme). It has been launched on June 1st, 2013 and will last 27 months.

Under the coordination of the French Ministry of Defence (Army Health Service – Percy Military Hospital) collaborating with Pherecydes Pharma (French SME), PHAGOBURN gathers six other international burn treatment centres – including the Royal Military Academy/Queen Astrid Military Hospital (Belgium) and the Lausanne University Hospital (Switzerland) – as well as a second French SME, Clean Cells.

The PHAGOBURN study aims at evaluating phage therapy (therapeutic use of bacteriophages) to treat skin infections caused by Escherichia coli and Pseudomonas aeruginosa bacteria in burn patients.

More information can be found online (http://cordis.europa.eu/search/index.cfm?fuseaction=proj.document&PJ_RCN=13907101)
or in the pdf Press Release Kit (290 KB) .